SG11201701745TA - Methods and compositions for enhancing immune responses - Google Patents
Methods and compositions for enhancing immune responsesInfo
- Publication number
- SG11201701745TA SG11201701745TA SG11201701745TA SG11201701745TA SG11201701745TA SG 11201701745T A SG11201701745T A SG 11201701745TA SG 11201701745T A SG11201701745T A SG 11201701745TA SG 11201701745T A SG11201701745T A SG 11201701745TA SG 11201701745T A SG11201701745T A SG 11201701745TA
- Authority
- SG
- Singapore
- Prior art keywords
- compositions
- methods
- immune responses
- enhancing immune
- enhancing
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
- A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/861—Adenoviral vectors
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
- C12N15/863—Poxviral vectors, e.g. entomopoxvirus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/10011—Adenoviridae
- C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
- C12N2710/10341—Use of virus, viral particle or viral elements as a vector
- C12N2710/10343—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24041—Use of virus, viral particle or viral elements as a vector
- C12N2710/24043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14111—Ebolavirus, e.g. Zaire ebolavirus
- C12N2760/14171—Demonstrated in vivo effect
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/14011—Filoviridae
- C12N2760/14211—Marburgvirus, e.g. lake Victoria marburgvirus
- C12N2760/14234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Virology (AREA)
- Microbiology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Tropical Medicine & Parasitology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462045522P | 2014-09-03 | 2014-09-03 | |
US201562116021P | 2015-02-13 | 2015-02-13 | |
US201562159823P | 2015-05-11 | 2015-05-11 | |
US201562189109P | 2015-07-06 | 2015-07-06 | |
PCT/US2015/048388 WO2016036971A1 (en) | 2014-09-03 | 2015-09-03 | Methods and compositions for enhancing immune responses |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201701745TA true SG11201701745TA (en) | 2017-04-27 |
Family
ID=54207690
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201701745TA SG11201701745TA (en) | 2014-09-03 | 2015-09-03 | Methods and compositions for enhancing immune responses |
Country Status (14)
Country | Link |
---|---|
US (1) | US10561722B2 (en) |
EP (1) | EP3188754A1 (en) |
JP (2) | JP2017527564A (en) |
KR (2) | KR20170072195A (en) |
CN (1) | CN107106673A (en) |
AP (1) | AP2017009822A0 (en) |
AU (1) | AU2015311868B2 (en) |
BR (1) | BR112017004202A2 (en) |
CA (1) | CA2960096A1 (en) |
EA (1) | EA201790507A1 (en) |
IL (1) | IL250818A0 (en) |
MX (1) | MX2017002890A (en) |
SG (1) | SG11201701745TA (en) |
WO (1) | WO2016036971A1 (en) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10925955B2 (en) | 2016-07-15 | 2021-02-23 | Janssen Vaccines & Prevention B.V. | Methods and compositions for inducing protective immunity against a Marburg virus infection |
WO2018011768A1 (en) * | 2016-07-15 | 2018-01-18 | Janssen Vaccines And Prevention B.V. | Methods and compositions for inducing protective immunity against a marburg virus infection |
EP3606553A1 (en) | 2017-04-06 | 2020-02-12 | Janssen Vaccines & Prevention B.V. | Mva-bn and ad26.zebov or ad26.filo prime-boost regimen |
JP2020518648A (en) | 2017-05-08 | 2020-06-25 | グリットストーン オンコロジー インコーポレイテッド | Alphavirus neonatal antigen vector |
CN111163799A (en) * | 2017-07-28 | 2020-05-15 | 扬森疫苗与预防公司 | Methods and compositions for heterologous repRNA immunization |
CA3099642A1 (en) * | 2018-05-23 | 2019-11-28 | Gritstone Oncology, Inc. | Immune checkpoint inhibitor co-expression vectors |
JP7437385B2 (en) | 2018-09-06 | 2024-02-22 | バヴァリアン・ノルディック・アクティーゼルスカブ | Poxvirus composition with improved storage |
WO2020232408A1 (en) * | 2019-05-15 | 2020-11-19 | Genocea Biosciences, Inc. | Treatment methods |
WO2020243719A1 (en) | 2019-05-30 | 2020-12-03 | Gritstone Oncology, Inc. | Modified adenoviruses |
AU2021233167A1 (en) | 2020-03-12 | 2022-09-22 | Bavarian Nordic A/S | Compositions improving poxvirus stability |
AU2021320896A1 (en) | 2020-08-06 | 2023-03-23 | Gritstone Bio, Inc. | Multiepitope vaccine cassettes |
WO2023198815A1 (en) | 2022-04-14 | 2023-10-19 | Janssen Vaccines & Prevention B.V. | Sequential administration of adenoviruses |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1341245C (en) | 1988-01-12 | 2001-06-05 | F. Hoffmann-La Roche Ag | Recombinant vaccinia virus mva |
US6083716A (en) | 1996-09-06 | 2000-07-04 | The Trustees Of The University Of Pennsylvania | Chimpanzee adenovirus vectors |
GB0023203D0 (en) | 2000-09-21 | 2000-11-01 | Isis Innovation | Vaccination method |
WO2000000616A2 (en) * | 1998-06-29 | 2000-01-06 | U.S. Medical Research Institute Of Infectious Diseases | Marburg virus vaccines |
US7033595B1 (en) * | 1998-08-04 | 2006-04-25 | Purdue Research Foundation | Pseudotyped retroviruses and stable cell lines for their production |
WO2000008131A2 (en) * | 1998-08-04 | 2000-02-17 | Purdue Research Foundation | Pseudotyped retroviruses and stable cell lines for their production |
ES2354578T3 (en) | 1999-05-17 | 2011-03-16 | Crucell Holland B.V. | ADENOVIRUS HUMAN SEROTIPO RECOMBINANT AD26. |
US6913922B1 (en) | 1999-05-18 | 2005-07-05 | Crucell Holland B.V. | Serotype of adenovirus and uses thereof |
DE60116371T3 (en) | 2000-11-23 | 2016-11-17 | Bavarian Nordic A/S | VARIANT OF THE MODIFIED VACCINIA ANKARA VIRUS |
AU2002347317B2 (en) | 2001-11-30 | 2008-06-26 | Isis Innovation Limited | Vaccine |
AU2002356690B2 (en) | 2001-12-04 | 2008-07-24 | Bavarian Nordic A/S | Flavivirus NS1 subunit vaccine |
IL164802A0 (en) | 2002-04-25 | 2005-12-18 | Crucell Holland Bv | Stable adenoviral vectors and methods for propagation thereof |
MXPA04008891A (en) | 2002-04-25 | 2004-11-26 | Crucell Holland Bv | Means and methods for the production of adenovirus vectors. |
CA2499385A1 (en) * | 2002-09-20 | 2004-04-01 | Crucell Holland B.V. | Modified adenoviral vectors for use in vaccines and gene therapy |
PL2163260T3 (en) | 2004-01-23 | 2017-12-29 | Msd Italia S.R.L. | Chimpanzee adenovirus vaccine carriers |
US8101739B2 (en) | 2004-09-27 | 2012-01-24 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant expression vectors comprising a human codon-optimized marburg virus (MARV) angola glycoprotein gene insert and method of immunization employing said vector |
US20100143302A1 (en) | 2006-03-16 | 2010-06-10 | Crucell Holland B.V. | Recombinant Adenoviruses Based on Serotype 26 and 48, and Use Thereof |
WO2009061739A1 (en) * | 2007-11-06 | 2009-05-14 | The Government Of The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Neutralization of hcv |
EP2350270B1 (en) * | 2008-10-24 | 2018-03-07 | The Government of the United States of America, as represented by the Secretary, Department of Health & Human Services | Human ebola virus species and compositions and methods thereof |
NZ591662A (en) * | 2008-11-21 | 2012-10-26 | Bavarian Nordic As | Vector comprising multiple homologous nucleotide sequences |
WO2010085984A1 (en) | 2009-02-02 | 2010-08-05 | Okairos Ag | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
CA3108979A1 (en) | 2009-02-02 | 2010-08-05 | Glaxosmithkline Biologicals Sa | Simian adenovirus nucleic acid- and amino acid-sequences, vectors containing same, and uses thereof |
CN101670102A (en) * | 2009-09-15 | 2010-03-17 | 中国科学院广州生物医药与健康研究院 | Method for combining poxvirus vector HIV vaccine and adenoviral vector HIV vaccine and application |
EP2529010B1 (en) | 2010-01-28 | 2017-04-19 | Bavarian Nordic A/S | Vaccinia virus mutants containing the major genomic deletions of mva |
ES2711613T3 (en) * | 2010-04-16 | 2019-05-06 | Us Gov Health & Human Services | Filovirus vaccines based on an adenovirus chimpanzee vector |
WO2012082918A1 (en) | 2010-12-14 | 2012-06-21 | The Goverment Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Adenovirus serotype 26 and serotype 35 filovirus vaccines |
CA2826594C (en) * | 2011-02-03 | 2019-09-17 | The Government Of The U.S.A., As Represented By The Secretary, Department Of Health & Human Services | Multivalent vaccines for rabies virus and filoviruses |
JP6389163B2 (en) * | 2012-04-12 | 2018-09-12 | ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア | Filovirus consensus antigen, nucleic acid construct, and vaccine produced therefrom, and method of use thereof |
WO2014005643A1 (en) | 2012-07-05 | 2014-01-09 | Okairos Ag | Novel prime-boosting regimens involving immunogenic polypeptides encoded by polynucleotides |
WO2014037124A1 (en) | 2012-09-04 | 2014-03-13 | Bavarian Nordic A/S | Methods and compositions for enhancing vaccine immune responses |
GB201303406D0 (en) * | 2013-02-26 | 2013-04-10 | Health Prot Agency | Crimean-Congo Haemorrhagic Fever Virus Antigenic Composition |
-
2015
- 2015-09-03 JP JP2017512836A patent/JP2017527564A/en active Pending
- 2015-09-03 WO PCT/US2015/048388 patent/WO2016036971A1/en active Application Filing
- 2015-09-03 AU AU2015311868A patent/AU2015311868B2/en active Active
- 2015-09-03 MX MX2017002890A patent/MX2017002890A/en unknown
- 2015-09-03 EA EA201790507A patent/EA201790507A1/en unknown
- 2015-09-03 CA CA2960096A patent/CA2960096A1/en not_active Abandoned
- 2015-09-03 EP EP15771771.1A patent/EP3188754A1/en not_active Withdrawn
- 2015-09-03 US US15/508,288 patent/US10561722B2/en active Active
- 2015-09-03 KR KR1020177008912A patent/KR20170072195A/en active Application Filing
- 2015-09-03 CN CN201580055345.XA patent/CN107106673A/en active Pending
- 2015-09-03 SG SG11201701745TA patent/SG11201701745TA/en unknown
- 2015-09-03 AP AP2017009822A patent/AP2017009822A0/en unknown
- 2015-09-03 BR BR112017004202A patent/BR112017004202A2/en not_active Application Discontinuation
- 2015-09-03 KR KR1020197015215A patent/KR20190062617A/en active Application Filing
-
2017
- 2017-02-27 IL IL250818A patent/IL250818A0/en unknown
-
2019
- 2019-03-28 JP JP2019063057A patent/JP2019123734A/en active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2017002890A (en) | 2017-11-13 |
KR20170072195A (en) | 2017-06-26 |
EP3188754A1 (en) | 2017-07-12 |
IL250818A0 (en) | 2017-04-30 |
JP2017527564A (en) | 2017-09-21 |
AU2015311868A1 (en) | 2017-04-20 |
BR112017004202A2 (en) | 2019-09-03 |
US10561722B2 (en) | 2020-02-18 |
WO2016036971A1 (en) | 2016-03-10 |
AU2015311868B2 (en) | 2018-11-22 |
CN107106673A (en) | 2017-08-29 |
KR20190062617A (en) | 2019-06-05 |
EA201790507A1 (en) | 2017-07-31 |
AP2017009822A0 (en) | 2017-03-31 |
CA2960096A1 (en) | 2016-03-10 |
JP2019123734A (en) | 2019-07-25 |
US20170340721A1 (en) | 2017-11-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1257295A1 (en) | Compositions and methods for immunooncology | |
GB2535253B (en) | Compositions and methods | |
GB2546350B (en) | Compositions and methods | |
IL250818A0 (en) | Methods and compositions for enhancing immune responses | |
IL250902A0 (en) | Anti-met antibodies and compositions | |
GB201718876D0 (en) | Antithrombin-heparin compositions and methods | |
IL247614A0 (en) | Methods and compositions for modifying the immune response | |
IL246879B (en) | Apilimod compositions and methods for using same | |
GB201417828D0 (en) | New methods and compositions | |
HK1245158A1 (en) | Apilimod compositions and methods for using same | |
HK1250637A1 (en) | Agents and compositions for eliciting an immune response | |
ZA201607571B (en) | Compositions and methods for detecting huanglongbing | |
SG11201701402QA (en) | Anti-tumor compositions and methods | |
EP3097420A4 (en) | Methods and compositions for immune dis-inhibition | |
ZA201703336B (en) | Novel products and methods | |
IL252190A0 (en) | Anti-hcmv compositions and methods | |
IL248877B (en) | Compositions and methods for enhancing immunity | |
PL3223846T3 (en) | Adjuvant compositions and related methods | |
GB201705626D0 (en) | Compositions and methods | |
ZA201807665B (en) | Methods and compositions | |
GB201715820D0 (en) | Compositions and methods | |
ZA201606811B (en) | Compositions and methods for identifying ehrlichia species | |
GB201512996D0 (en) | Compositions and methods | |
GB201514413D0 (en) | Compositions and methods | |
PL3161011T3 (en) | Methods and compositions for processing dietary fibers |